Barbieri Elisa, Wang Yuxi, Cantarutti Anna, Scamarcia Antonio, Cantarutti Luigi, Corrao Giovanni, Torbica Aleksandra, Giaquinto Carlo
Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padua, 35100 Padua, Italy.
Centre for Research on Health and Social Care Management, Bocconi University, 20136 Milan, Italy.
Vaccines (Basel). 2024 Sep 28;12(10):1113. doi: 10.3390/vaccines12101113.
: Seasonal influenza annually puts a significant burden on the pediatric population, especially the youngest, causing severe illness and death. Additionally, associated healthcare costs cause a significant financial strain on healthcare systems. While vaccination is the most effective prevention method, its cost-effectiveness for healthy children remains unassessed. : Using the Pedianet database spanning from 2009 to 2019, we analyzed influenza cases among 6-month-olds to 14-year-olds in Italy. Data included influenza-related medical visits, prescriptions, exams, emergency visits, hospitalizations, and costs. Adverse events and quality-adjusted life years (QALYs) were considered from the existing literature. A static decision-tree model compared annual vaccination strategies, assessing probabilities for influenza or influenza-like illnesses by vaccination status. Incremental cost-effectiveness ratios (ICERs) were calculated, along with sensitivity analyses and cost-effectiveness acceptability curve generation. : Mean total influenza costs for vaccinated children averaged EUR 18.6 (range 0-3175.9, including EUR 15.79 for the influenza vaccination), whereas costs for unvaccinated children were consistently lower at around EUR 4.6 (range 0-3250.1). The average ICER for years where vaccine and virus strains are matched was EUR 29,831 per QALY, which is below the EUR 40,000 threshold set by the Italian National Health Services. The ICER values range from EUR 13,736 (2017/2018) to EUR 72,153 (2013/2014). Averted influenza costs averaged EUR 23 per case, with fluctuations over the years. In most observed years, influenza vaccination was cost-effective from the healthcare providers' standpoint. The exception was 2009-2010, due to a mismatch between vaccine and virus strains. : This study highlights the economic viability of influenza vaccination, especially when virus and vaccine strains align. It demonstrates the potential of vaccination programs in preserving children's health and well-being while managing healthcare costs.
季节性流感每年都会给儿童群体,尤其是年龄最小的儿童带来沉重负担,导致严重疾病和死亡。此外,相关的医疗费用给医疗系统造成了巨大的经济压力。虽然接种疫苗是最有效的预防方法,但其对健康儿童的成本效益仍未得到评估。
利用2009年至2019年的Pedianet数据库,我们分析了意大利6个月至14岁儿童中的流感病例。数据包括与流感相关的就诊、处方、检查、急诊、住院和费用。从现有文献中考虑了不良事件和质量调整生命年(QALY)。一个静态决策树模型比较了年度疫苗接种策略,根据疫苗接种状况评估流感或流感样疾病的概率。计算了增量成本效益比(ICER),并进行了敏感性分析和成本效益可接受性曲线生成。
接种疫苗儿童的平均流感总费用为18.6欧元(范围为0至3175.9欧元,包括流感疫苗接种费用15.79欧元),而未接种疫苗儿童的费用一直较低,约为4.6欧元(范围为0至3250.1欧元)。疫苗和病毒株匹配年份的平均ICER为每QALY 29,831欧元,低于意大利国家卫生服务部门设定的40,000欧元阈值。ICER值范围从13,736欧元(2017/2018年)到72,153欧元(2013/2014年)。每例避免的流感费用平均为23欧元,多年来有所波动。在大多数观察年份,从医疗服务提供者的角度来看,流感疫苗接种具有成本效益。例外情况是2009 - 2010年,由于疫苗和病毒株不匹配。
这项研究强调了流感疫苗接种的经济可行性,特别是当病毒和疫苗株匹配时。它展示了疫苗接种计划在保护儿童健康和福祉以及控制医疗成本方面的潜力。